Introduction: The Intersection of Insulin Pharmacokinetics and Automated Delivery

Closed loop insulin delivery systems, also known as artificial pancreas systems, represent a transformative advance in the management of type 1 diabetes. These systems integrate a continuous glucose monitor, an insulin pump, and a control algorithm that automates insulin delivery in response to real-time glucose readings. The primary goal is to keep blood glucose levels within a target range—typically 70–180 mg/dL—while reducing the cognitive burden on the user. However, the performance of any closed loop system depends heavily on the insulin used. The pharmacokinetic profile of the insulin—its onset, peak, and duration—must align with the algorithm's expectations. If the insulin acts too slowly, too unpredictably, or too long, the algorithm cannot maintain safe and tight glycemic control. This article provides a detailed examination of which insulin types are compatible with closed loop systems, why rapid-acting insulins are the standard, and the risks associated with using off-label or incompatible formulations.

Fundamentals of Closed Loop Insulin Delivery

A closed loop system functions as a continuous feedback loop. The continuous glucose monitor measures interstitial glucose levels every one to five minutes. This data feeds into a control algorithm that calculates the appropriate insulin dose and directs the pump to deliver it. The algorithm may be hosted on a dedicated controller, a smartphone application, or directly on the pump itself. Depending on the degree of automation, systems are classified as hybrid closed loop—where the user still manually administers meal boluses—or fully closed loop, which is still emerging and aims to handle all insulin needs, including meals, automatically.

As of 2025, the most widely used FDA-approved hybrid closed loop systems include the Medtronic MiniMed 780G with SmartGuard technology, the Tandem t:slim X2 with Control-IQ, and the Insulet Omnipod 5. Each system uses a different control approach—proportional-integral-derivative, model predictive control, or fuzzy logic—but all share the same fundamental requirement: the insulin must act rapidly enough to correct hyperglycemia and prevent hypoglycemia in real time. The algorithm cannot wait hours for the insulin to take effect; it requires a predictable and swift pharmacokinetic response to maintain stability.

Classification of Insulins and Their Relevance to Pump Therapy

Insulin preparations are categorized by their onset, peak, and duration of action. Understanding these categories is essential for selecting the right insulin for a closed loop system.

  • Rapid-acting insulin analogs: These include insulin lispro (Humalog), insulin aspart (NovoLog/NovoRapid), insulin glulisine (Apidra), and faster-acting insulin aspart (Fiasp). Onset is 5–15 minutes, peak occurs at 1–2 hours, and duration is 3–5 hours. These insulins are designed for subcutaneous delivery and have consistent, reproducible absorption profiles.
  • Short-acting regular insulin: Onset is approximately 30 minutes, peak at 2–4 hours, and duration 5–8 hours. Regular insulin was used in early insulin pumps but has largely been replaced by rapid-acting analogs due to its slower onset and less predictable action.
  • Intermediate-acting insulin: Examples include NPH (Neutral Protamine Hagedorn) insulin. Onset is 2–4 hours, peak at 4–12 hours, and duration 12–18 hours. NPH has significant variability in absorption and is not suitable for pump use.
  • Long-acting insulin: This category includes insulin glargine (Lantus, Toujeo), insulin detemir (Levemir), and insulin degludec (Tresiba). These insulins have an onset of 2–4 hours, no pronounced peak, and a duration of 20–42 hours. They are designed for once-daily or twice-daily basal injection therapy and are not formulated for pump delivery.
  • Concentrated insulins: Examples include insulin lispro U-200, insulin degludec U-200, and regular insulin U-500. These contain higher concentrations of insulin per milliliter and are intended for subcutaneous injection in insulin-resistant patients. They are not approved for use in standard insulin pumps because the pump's basal delivery increments are calibrated for U-100 concentration, and using concentrated insulin increases the risk of dosing errors.

For closed loop systems, the choice is essentially limited to rapid-acting insulin analogs. The algorithm requires precise, repeatable, and rapid insulin action to respond to the minute-by-minute fluctuations in glucose levels that occur throughout the day.

Why Rapid-Acting Insulin Is the Foundation of Closed Loop Therapy

The closed loop algorithm performs continuous adjustments to the basal insulin delivery rate—increasing it when glucose is rising, decreasing or suspending it when glucose is falling. The system can also deliver automatic correction boluses. For these adjustments to be both safe and effective, the insulin must have a very short delay between delivery and measurable effect. Rapid-acting insulins are engineered specifically for this purpose.

Clinical trials and real-world studies have consistently demonstrated that hybrid closed loop systems using rapid-acting insulin analogs achieve significantly higher time-in-range and lower rates of hypoglycemia compared to open-loop pump therapy. The pharmacokinetic consistency of modern rapid-acting analogs allows the algorithm to build reliable models of insulin-on-board, which is critical for predicting glucose trends and avoiding over-delivery. For instance, the Medtronic 780G SmartGuard algorithm uses the user's total daily insulin and the action curve of the specific insulin to estimate how much insulin remains active at any given time. If the insulin action curve changes—as it would with a different insulin type—the algorithm's predictions become inaccurate, leading to suboptimal control.

Another practical consideration is the stability of insulin at body temperature. Insulin pumps hold a reservoir that is worn on the body for several days. Rapid-acting insulins are formulated to remain stable at near-body temperature for two to seven days, even as the user goes about daily activities. In contrast, long-acting insulins are not stable under these conditions; they can form visible aggregates, alter their absorption characteristics, and cause occlusion alarms. The physical stability of insulin in the pump environment is a non-negotiable requirement for reliable automated delivery.

The Incompatibility of Long-Acting and Intermediate-Acting Insulins

Long-acting insulins are designed for once- or twice-daily injection therapy. They achieve a prolonged, flat effect through specific mechanisms—precipitation at the injection site for glargine, binding to albumin for detemir and degludec. These properties make them completely unsuitable for closed loop systems for several reasons.

Slow onset: Even if delivered via a pump, a long-acting insulin would not reach effective levels for hours. The algorithm's adjustments would have no immediate effect, and the system would fail to respond to rapid glucose changes. This delay could lead to prolonged hyperglycemia and increase the risk of diabetic ketoacidosis.

Lack of peaking and prolonged duration: The algorithm relies on the ability to deliver small pulses of insulin that are quickly absorbed and then cleared from the circulation. Long-acting insulins accumulate, creating a reservoir effect that cannot be quickly turned off. If the system over-delivers—either due to algorithm error or user mis-calibration—the prolonged duration of action significantly increases the risk of late, severe hypoglycemia, including during sleep.

Physical instability in pumps: Insulin glargine, for example, forms microprecipitates in its vial formulation. When placed in a pump reservoir, these precipitates can clog the infusion set tubing, causing unpredictable delivery or complete occlusion. Insulin degludec and detemir are also not formulated for pump use and will degrade over time at body temperature, leading to reduced potency and altered pharmacokinetics.

Regulatory and safety warnings: No major closed loop system manufacturer recommends or supports the use of long-acting or intermediate-acting insulins in their pumps. Using these insulins off-label voids the manufacturer's warranty and, more importantly, puts the patient at risk of serious harm. The FDA has issued clear guidance that only rapid-acting insulin analogs should be used in approved artificial pancreas systems.

Experimental research has explored the use of diluted long-acting insulin in pumps for specific clinical situations, but this remains outside standard practice and is not compatible with current automated algorithms. The consensus among diabetes technology experts is clear: long-acting insulins have no place in closed loop systems.

Current FDA-Approved Systems and Their Approved Insulins

Medtronic MiniMed 780G

The Medtronic MiniMed 780G system is approved for use with insulin lispro (Humalog) and insulin aspart (NovoLog/NovoRapid). In some regions, faster-acting insulin aspart (Fiasp) is also approved for use with the 780G, though labeling varies by country. Medtronic explicitly warns against using any concentrated insulin formulation—including U-500, U-200, or U-300—in their pumps. The system's SmartGuard algorithm is specifically tuned for the pharmacokinetic profile of U-100 rapid-acting analogs.

Tandem t:slim X2 with Control-IQ

The Tandem t:slim X2 with Control-IQ technology is approved for insulin lispro, insulin aspart, and faster-acting insulin aspart (Fiasp). Tandem conducted large-scale clinical trials—including the pivotal Control-IQ study—using these insulins, and the algorithm was tuned based on their pharmacokinetic profiles. Using any other insulin type will lead to unpredictable glycemic outcomes and may violate the terms of use. Tandem also recommends against using U-200 or other concentrated formulations.

Insulet Omnipod 5

The Insulet Omnipod 5 system is approved for insulin lispro and insulin aspart. Fast-acting insulin aspart (Fiasp) can also be used based on clinical data and labeling in many countries. The Omnipod 5's algorithm is designed for rapid-acting insulins, and the system's SmartBolus Calculator relies on the action curve of these insulins. Concentrated insulins are not recommended, as the pump's basal delivery increments—typically 0.05 units per hour—are too coarse for safe automated titration with U-200 or U-500 formulations.

All three systems require U-100 rapid-acting insulin. The algorithms assume a specific insulin action curve, and using a different formulation changes that curve, degrading control and increasing risk.

Challenges and Risks of Off-Label Insulin Use in Closed Loop Systems

Regular Insulin in Pumps

Some users with insulin resistance or those with limited access to rapid-acting analogs may consider using regular insulin (U-100 R) in their closed loop system. While regular insulin has a shorter duration than long-acting insulins, its onset is slower—approximately 30 minutes—and its peak is less pronounced. Algorithms designed for rapid-acting analogs will interpret the delayed effect as insulin resistance and may escalate the dose, leading to a cascade of over-delivery and late hypoglycemia. The consensus among experts is that regular insulin should not be used in modern hybrid closed loop systems.

Concentrated Insulins (U-500, U-200)

Concentrated insulins are intended for patients with severe insulin resistance who require high doses. Using U-500 insulin in a pump designed for U-100 creates a serious dosing hazard: if the user or algorithm programs a dose based on U-100 units, the actual delivered dose will be five times higher. This can cause profound, life-threatening hypoglycemia. Even if the user correctly accounts for the concentration, the pump's basal increments may not be fine enough to allow safe automated titration. No closed loop system manufacturer supports the use of concentrated insulins.

Inhaled Insulin

Inhaled insulin (Afrezza) is a rapid-acting insulin delivered via inhalation into the lungs. It has an ultra-rapid onset of 12–15 minutes and a short duration of about 2–3 hours. However, it cannot be used in a pump, as it is not a subcutaneous formulation. There are no closed loop systems that incorporate inhaled insulin, and the current algorithms are designed for subcutaneous delivery. Inhaled insulin has no role in pump-based automated delivery at this time.

Insulin Stability and Storage Considerations for Pump Users

Insulin in a pump reservoir is exposed to body temperature—typically around 37°C at the skin surface—and continuous motion. Heat and agitation can degrade insulin over time, reducing its potency and altering its pharmacokinetic profile. Rapid-acting analogs such as insulin lispro and insulin aspart are stable for up to seven days in a pump reservoir at body temperature, though the infusion set itself must be changed every 2–3 days to reduce the risk of infection or occlusion.

Faster-acting insulin aspart (Fiasp) has a slightly shorter stability window; the manufacturer recommends replacing the reservoir every six days. Users must strictly follow these guidelines. Using insulin beyond its recommended stability window can lead to a gradual loss of glycemic control and an increased risk of hyperglycemia. Signs of degraded insulin include unexpected glucose rises, increased frequency of occlusion alarms, or visible cloudiness or particles in the reservoir.

Long-acting insulins degrade more rapidly at body temperature and may form visible aggregates within 24–48 hours in a pump reservoir. This degradation alters the absorption characteristics and makes the insulin action unpredictable. For this reason alone, long-acting insulins should never be used in a pump.

Future Directions: Ultra-Rapid Insulins and Next-Generation Systems

Pharmaceutical companies continue to develop ultra-rapid insulins with even faster onset and shorter duration of action. Faster-acting insulin aspart (Fiasp) is already approved and used in many closed loop systems. Other candidates include BioChaperone Lispro and inhaled insulin formulations that are being designed for compatibility with automated delivery systems. Ultra-rapid insulins may enable closed loop algorithms to achieve better postprandial control by reducing the delay between the algorithm's decision and the insulin's effect. This could reduce time in hyperglycemia after meals and potentially lower the risk of hypoglycemia because the algorithm can correct more quickly.

Another active area of research is dual-hormone closed loop systems, which deliver both insulin and glucagon. In these systems, a second pump delivers glucagon—a hormone that raises blood glucose—to counteract severe hypoglycemia. While such systems still require a rapid-acting insulin as the primary hormone, the addition of glucagon provides a safety buffer that may relax the insulin action requirements slightly. Clinical trials of dual-hormone systems have shown promising results, but these systems are not yet widely available outside of research settings.

In the longer term, we may see insulins specifically formulated for pump use, with tailored absorption rates and improved thermal stability. Researchers are also exploring the use of smart insulin molecules that change their activity based on glucose concentration. However, for the foreseeable future, U-100 rapid-acting insulin analogs remain the standard of care for all approved closed loop systems.

Practical Recommendations for Users and Clinicians

  1. Adhere to approved insulins: Use only rapid-acting insulin analogs approved by your pump manufacturer—lispro (Humalog), aspart (NovoLog), or glulisine (Apidra). Fast-acting insulin aspart (Fiasp) is approved for use in Tandem and Omnipod systems per labeling. Always verify compatibility with your specific device.
  2. Replace reservoirs and infusion sets on schedule: Change infusion sets every 2–3 days to reduce absorption variability and infection risk. Replace reservoirs according to the insulin manufacturer's stability guidelines—every 6–7 days for standard rapid-acting insulins, and every 6 days for Fiasp.
  3. Do not mix insulins: Never mix a long-acting, intermediate-acting, or concentrated insulin with a rapid-acting insulin in the same reservoir. The algorithm assumes a fixed pharmacokinetic profile; mixing leads to unpredictable action and loss of glycemic control.
  4. Monitor for site issues: Regularly inspect infusion sites for signs of lipohypertrophy—hardened, fatty lumps caused by repeated injections at the same site—which can affect insulin absorption. Rotate sites consistently, and use new sites if you notice unexpected glucose patterns.
  5. Consult your healthcare team: Any change in insulin type or concentration should be discussed with your endocrinologist or certified diabetes educator. Insurance formularies may also restrict coverage to specific insulins that are compatible with your pump brand.
  6. Avoid off-label use: Using unapproved insulins in a closed loop system voids the manufacturer's warranty and carries serious risks, including severe hypoglycemia, hyperglycemia, diabetic ketoacidosis, and infusion set occlusion. Do not experiment with off-label insulins without direct medical supervision.

Conclusion

Closed loop insulin delivery systems have fundamentally improved the management of type 1 diabetes by automating insulin delivery based on real-time glucose data. The insulin used in these systems is not a minor detail—it is the critical element that determines whether the algorithm can operate safely and effectively. Rapid-acting insulin analogs—lispro, aspart, glulisine, and faster-acting aspart—are the only insulins approved for use in current hybrid closed loop systems. Their pharmacokinetic profiles match the dynamic requirements of the control algorithm, allowing for precise and timely corrections. Long-acting, intermediate-acting, and concentrated insulins are incompatible and can cause serious, potentially life-threatening harm if used in a closed loop system.

As technology evolves, ultra-rapid insulins may expand the range of compatible options, and dual-hormone systems may offer additional safety margins. For now, strict adherence to manufacturer recommendations—using only approved U-100 rapid-acting insulins and following proper reservoir and infusion set change schedules—ensures the best possible outcomes. Always consult a healthcare professional before making any changes to your insulin regimen or pump settings. For further reading, see the FDA's overview of artificial pancreas device systems, a comparative study of insulin types in closed loop systems, and the pharmacokinetic considerations for insulin pump therapy.